Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators. Cannon CP, et al. Among authors: frey mj. N Engl J Med. 2001 Jun 21;344(25):1879-87. doi: 10.1056/NEJM200106213442501. N Engl J Med. 2001. PMID: 11419424 Free article. Clinical Trial.
Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E; TACTICS-TIMI 18 Investigators. Morrow DA, et al. Among authors: frey mj. JAMA. 2001 Nov 21;286(19):2405-12. doi: 10.1001/jama.286.19.2405. JAMA. 2001. PMID: 11712935 Clinical Trial.
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Cannon CP, Gibson CM, McCabe CH, Adgey AA, Schweiger MJ, Sequeira RF, Grollier G, Giugliano RP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E. Cannon CP, et al. Among authors: frey m. Circulation. 1998 Dec 22-29;98(25):2805-14. doi: 10.1161/01.cir.98.25.2805. Circulation. 1998. PMID: 9860780 Clinical Trial.
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials.
Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. Giugliano RP, et al. Among authors: frey mj. Am Heart J. 2000 Jul;140(1):81-93. doi: 10.1067/mhj.2000.107172. Am Heart J. 2000. PMID: 10874267 Clinical Trial.
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
Antman EM, Gibson CM, de Lemos JA, Giugliano RP, McCabe CH, Coussement P, Menown I, Nienaber CA, Rehders TC, Frey MJ, Van der Wieken R, Andresen D, Scherer J, Anderson K, Van de Werf F, Braunwald E. Antman EM, et al. Among authors: frey mj. Eur Heart J. 2000 Dec;21(23):1944-53. doi: 10.1053/euhj.2000.2243. Eur Heart J. 2000. PMID: 11071800 Clinical Trial.
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial.
de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, Coulter SA, Anderson K, Scherer J, Frey MJ, Van Der Wieken R, Van De Werf F, Braunwald E. de Lemos JA, et al. Among authors: frey mj. Circulation. 2000 Jan 25;101(3):239-43. doi: 10.1161/01.cir.101.3.239. Circulation. 2000. PMID: 10645918 Clinical Trial.
Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction.
Gibson CM, Murphy S, Menown IB, Sequeira RF, Greene R, Van de Werf F, Schweiger MJ, Ghali M, Frey MJ, Ryan KA, Marble SJ, Giugliano RP, Antman EM, Cannon CP, Braunwald E. Gibson CM, et al. Among authors: frey mj. J Am Coll Cardiol. 1999 Nov 1;34(5):1403-12. doi: 10.1016/s0735-1097(99)00397-6. J Am Coll Cardiol. 1999. PMID: 10551685
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F; ACUTE II Investigators. Cohen M, et al. Among authors: frey mj. Am Heart J. 2002 Sep;144(3):470-7. doi: 10.1067/mhj.2002.126115. Am Heart J. 2002. PMID: 12228784 Clinical Trial.
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators. Ferguson JJ, et al. Among authors: frey mj. JAMA. 2004 Jul 7;292(1):45-54. doi: 10.1001/jama.292.1.45. JAMA. 2004. PMID: 15238590 Clinical Trial.
51 results